Caroline Bello1, Arne Roseth2, Jordi Guardiola3, Catherine Reenaers1, Alexandra Ruiz-Cerulla3, Catherine Van Kemseke1, Claudia Arajol3, Christian Reinhard4, Laurence Seidel5, Edouard Louis6. 1. Department of Gastroenterology, University Hospital CHU of Liège, Belgium. 2. Department of Medicine, Section of Gastroenterology, Lovisenberg Diaconal Hospital, Oslo, Norway. 3. Department of Gastroenterology, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. 4. BÜHLMANN Laboratories AG, Schönenbuch, Switzerland. 5. Department of Biostatistics and Medico-economic Information, University Hospital, CHU of Liège, Belgium. 6. Department of Gastroenterology, University Hospital CHU of Liège, Belgium. Electronic address: edouard.louis@ulg.ac.be.
Abstract
The aim of our work was to test the usability of fecal calprotectin (FC) home-based test in inflammatory bowel disease (IBD) patients. METHODS: IBD patients were prospectively recruited. They had to measure FC with a dedicated tool and smartphone application, 5 times at two weeks intervals over an 8 weeks period. They had to fill in a usability questionnaire at the first and the last FC measurement. A System Usability Scale (SUS: 0-100) and the Global Score of Usability (GSU: 0-85) were calculated. FC was also centrally measured by ELISA. RESULTS: Fifty-eight patients were recruited. Forty-two performed at least one FC measurement and 27 performed all the FC requested measurements. The median (IQR) SUS (0-100) at the first and last use were 85 (78-90) and 81 (70-88), respectively; the median (IQR) GSU (0-85) at the first and last use were 74 (69-80) and 77 (68-83), respectively. Adherence to the planned measurements and usability of the tool were higher in females and in less severe disease. The intra-class correlation coefficient between home-based and centrally measured FC was 0.88. CONCLUSION: The adherence to home-based measurement of FC was fair. Usability scores for the home-based test were high. There was a good correlation with the centrally measured FC by ELISA.
The aim of our work was to test the usability of fecal calprotectin (FC) home-based test in inflammatory bowel disease (IBD) patients. METHODS:IBDpatients were prospectively recruited. They had to measure FC with a dedicated tool and smartphone application, 5 times at two weeks intervals over an 8 weeks period. They had to fill in a usability questionnaire at the first and the last FC measurement. A System Usability Scale (SUS: 0-100) and the Global Score of Usability (GSU: 0-85) were calculated. FC was also centrally measured by ELISA. RESULTS: Fifty-eight patients were recruited. Forty-two performed at least one FC measurement and 27 performed all the FC requested measurements. The median (IQR) SUS (0-100) at the first and last use were 85 (78-90) and 81 (70-88), respectively; the median (IQR) GSU (0-85) at the first and last use were 74 (69-80) and 77 (68-83), respectively. Adherence to the planned measurements and usability of the tool were higher in females and in less severe disease. The intra-class correlation coefficient between home-based and centrally measured FC was 0.88. CONCLUSION: The adherence to home-based measurement of FC was fair. Usability scores for the home-based test were high. There was a good correlation with the centrally measured FC by ELISA.
Authors: Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet Journal: United European Gastroenterol J Date: 2021-05-07 Impact factor: 4.623
Authors: Julie Hejl; Klaus Theede; Brian Møllgren; Kirsten Vikkelsø Madsen; Ashraf Heidari; Anna Á Steig; Mogens Fenger Journal: Pract Lab Med Date: 2017-11-21
Authors: Sjoukje-Marije Haisma; Anne Galaurchi; Shatha Almahwzi; Joy A Adekanmi Balogun; Anneke C Muller Kobold; Patrick F van Rheenen Journal: PLoS One Date: 2019-04-18 Impact factor: 3.240